US 10647715
KRas G12C inhibitors
granted A61PA61P35/00
Quick answer
US patent 10647715 (KRas G12C inhibitors) held by Mirati Therapeutics, Inc. expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61P, A61P35/00